MedPath

SUSAN CHANG

🇦🇺Australia
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

5

Active:1
Completed:1

Trial Phases

2 Phases

Phase 1:3
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (75.0%)
Phase 2
1 (25.0%)

Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma

Phase 1
Recruiting
Conditions
Recurrent World Health Organization (WHO) Grade II Glioma
WHO Grade II Glioma
Recurrent WHO Grade III Glioma
WHO Grade III Glioma
Interventions
Procedure: Magnetic Resonance Imaging
Procedure: Magnetic Resonance Spectroscopic Imaging
First Posted Date
2020-09-07
Last Posted Date
2025-01-10
Lead Sponsor
Susan Chang
Target Recruit Count
300
Registration Number
NCT04540107
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma

Phase 1
Active, not recruiting
Conditions
Glioblastoma Multiforme (GBM)
Interventions
Drug: Hyperpolarized 13C Pyruvate
First Posted Date
2019-07-15
Last Posted Date
2024-12-04
Lead Sponsor
Susan Chang
Target Recruit Count
17
Registration Number
NCT04019002
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

Hyperpolarized Imaging in Diagnosing Participants With Glioma

Phase 1
Recruiting
Conditions
Glioma
Interventions
Radiation: Hyperpolarized Carbon C 13 Pyruvate
Procedure: Magnetic Resonance Imaging
Radiation: Radiation Therapy
Drug: Chemotherapy
First Posted Date
2018-11-13
Last Posted Date
2024-11-19
Lead Sponsor
Susan Chang
Target Recruit Count
140
Registration Number
NCT03739411
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

68Ga-citrate PET/MR Imaging for Glioma

Terminated
Conditions
Glioma
Interventions
Drug: 68Ga-citrate PET/MR
First Posted Date
2017-11-07
Last Posted Date
2020-05-01
Lead Sponsor
Susan Chang
Target Recruit Count
2
Registration Number
NCT03335280
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

Everolimus in Treating Patients With Recurrent Low-Grade Glioma

Phase 2
Completed
Conditions
Adult Subependymal Giant Cell Astrocytoma
Adult Diffuse Astrocytoma
Adult Mixed Glioma
Adult Oligodendroglioma
Recurrent Adult Brain Neoplasm
Interventions
Other: Archival Tissue Analysis
First Posted Date
2009-01-15
Last Posted Date
2020-07-28
Lead Sponsor
Susan Chang
Target Recruit Count
58
Registration Number
NCT00823459
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.